Lawsuit Filed Against ARS Pharmaceuticals Over Caremark Formulary Inclusion
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Caremark added Neffy to its formulary on September 22, 2026. On the same date, a class action lawsuit was filed against ARS Pharmaceuticals by Schall, Brown & Schwartz LLP. The complaint alleges that ARS Pharmaceuticals made false and misleading statements to the market. Specifically, the lawsuit claims ARS knew or recklessly disregarded the risk of timeline problems related to CVS Caremark's inclusion of Neffy in its formulary.
From prnewswire.com
Why it matters
The lawsuit centers on ARS Pharmaceuticals' public statements regarding the timeline for insurance coverage of Neffy. Since ARS Pharmaceuticals' market viability is functionally dependent on Caremark's formulary inclusion and insurance coverage decisions, the allegations suggest that ARS Pharmaceuticals' commercialization plans could be impacted by shifts in coverage timelines.
ARS Pharmaceuticals relied on Caremark for expanded insurance coverage starting August 1, 2026.
From prnewswire.com
Who's involved
- CaremarkThe pharmacy benefits manager that added Neffy to its formulary.
- ARSThe pharmaceutical company facing the class action lawsuit over market statements.
- CVS HealthThe parent company of Caremark.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- ARSSpeculative
ARS Pharmaceuticals could see its commercialization plans impacted if the timeline for Neffy's insurance coverage shifts considerably.
Keep exploring
The entities involved
-
Caremark
Care franchise based in the United Kingdom
Nothing else this week.